Drugs / Bifico

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT01934959 Jan 2008 → Jan 2010 enterocolitis Tongji Hospital Completed No outcome recorded
Phase 21 trial
Phase 2 NCT04699721 Jul 2020 → Sep 2027 expected non-small cell lung carcinoma Xiangya Hospital of Central South University Active not recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT03642548 Feb 2019 → Mar 2024 Shanghai 10th People's Hospital Unknown No outcome recorded
Phase not applicable3 trials
NCT04131803 Oct 2021 → Nov 2022 colorectal cancer Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
NCT05178524 Jun 2021 → May 2022 hepatocellular carcinoma Tongji Hospital Completed No outcome recorded
NCT03379597 Nov 2017 → May 2021 bipolar disorder, schizophrenia Central South University Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Bifico “as well as BiFico (oral taking, 4 capsules/time, 2 times per day)” NCT04699721
5

NCT01934959

NCT03642548

NCT03379597

NCT04131803

NCT05178524

Known as bifidobacterium trifidum live powder “Bifico (also known as "bifidobacterium trifidum live powder") is a probiotic preparation that has been marketed and widely used in China.” NCT04131803
Known as Bifidobacterium trifidum live powder (BiFico, SINE) Bifidobacterium trifidum live powder (BiFico, SINE)NCT04699721
Modality Other / unclassified “Bifico (also known as "bifidobacterium trifidum live powder") is a probiotic preparation” NCT04131803
Route Oral “Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)” NCT03379597